Result of AGM

Summary by AI BETAClose X

Oxford Nanopore Technologies plc announced that all resolutions presented at its Annual General Meeting on June 4, 2026, were passed by shareholders. Key resolutions included the approval of the Directors' Report and Audited Statement of Accounts for the year ended December 31, 2025, with 99.99% of votes in favour, and the Directors' Remuneration Report with 98.61% in favour. The election and re-election of all directors were also approved with strong majorities, ranging from 94.62% to 99.95% in favour. Furthermore, shareholders approved the appointment of Deloitte LLP as auditors by 99.10% and authorised the board to allot shares and disapply pre-emption rights with significant support, including 96.59% and 97.07% respectively for share allotment and pre-emption rights. The company also received strong backing for market purchases and holding general meetings on shorter notice.

Disclaimer*

Oxford Nanopore Technologies plc
04 June 2026
 

04 June 2026

Oxford Nanopore Technologies plc

(the "Company")

Results of Annual General Meeting

 

The Annual General Meeting of the Company was held earlier today. All resolutions, as set out in the Company's Notice of Annual General Meeting dated 1 May 2026, were passed by the appropriate majority on a poll. Details of the poll results are set out below.

 

Oxford Nanopore Technologies plc Annual General Meeting Poll Results:

 

 

No.

RESOLUTION

VOTES
FOR

%

VOTES
AGAINST

%

VOTES
TOTAL

% of ISC VOTED

VOTES
WITHHELD

1.

To receive and consider the Directors' report, the Audited Statement of Accounts and Auditor's Report of the Company for the financial year ended 31 December 2025

644,479,235

99.99%

53,609

0.01%

644,532,844

66.25%

5,809,438

2.

To receive and approve the Directors' Remuneration Report for the year ended 31 December 2025

635,703,914

98.61%

8,979,992

1.39%

644,683,906

66.26%

5,658,376

3.

To elect Francis Van Parys as a director of the Company

644,496,369

99.95%

346,047

0.05%

644,842,416

66.28%

5,499,866

4.

To re-elect Dr Sarah Fortune as a director of the Company

642,145,731

98.77%

8,001,129

1.23%

650,146,860

66.82%

195,422

5.

To re-elect Adrian Hennah as a director of the Company

641,793,032

98.72%

8,342,451

1.28%

650,135,483

66.82%

206,799

6.

To re-elect Nicholas Keher as a director of the Company

644,012,773

99.05%

6,193,516

0.95%

650,206,289

66.83%

135,993

7.

To re-elect Dr Daniel Mahony as a director of the Company

642,158,034

99.60%

2,599,012

0.40%

644,757,046

66.27%

5,585,236

8.

To re-elect John O'Higgins as a director of the Company

641,833,262

99.55%

2,923,769

0.45%

644,757,031

66.27%

5,585,251

9.

To re-elect Dr Heather Preston as a director of the Company

641,939,772

98.74%

8,206,188

1.26%

650,145,960

66.82%

196,322

10. 

To re-elect Katherine (Kate) Priestman as a director of the Company

642,128,939

98.77%

8,017,121

1.23%

650,146,060

66.82%

196,222

11. 

To re-elect Duncan Tatton-Brown as a director of the Company

615,129,122

94.62%

34,986,815

5.38%

650,115,937

66.82%

226,345

12. 

To appoint Deloitte LLP as auditors of the Company

638,710,166

99.10%

5,822,215

0.90%

644,532,381

66.25%

5,809,901

13. 

To authorise the Audit & Risk Committee to determine the remuneration of the auditors

639,055,685

99.11%

5,769,712

0.89%

644,825,397

66.28%

5,516,885

14. 

To authorise the board of directors to allot shares

622,831,323

96.59%

21,984,854

3.41%

644,816,177

66.28%

5,526,105

15. 

To disapply pre-emption rights*

625,847,515

97.07%

18,881,645

2.93%

644,729,160

66.27%

5,613,122

16. 

To further disapply pre-emption rights*

620,910,261

96.31%

23,811,090

3.69%

644,721,351

66.27%

5,620,931

17. 

To authorise the Company to make market purchases*

644,443,311

99.94%

368,535

0.06%

644,811,846

66.28%

5,530,436

18. 

To authorise the Company to hold any general meeting (other than an Annual General Meeting) on not less than 14 clear days' notice*

631,898,194

97.99%

12,938,231

2.01%

644,836,425

66.28%

5,505,857

19. 

To authorise UK political expenditure not exceeding £100,000

642,283,505

99.77%

1,512,176

0.23%

643,795,681

66.17%

6,546,601

 

* Special Resolution

 

NOTES:

 

1.   Votes "For" and "Against" are expressed as a percentage of votes received.

 

2.   The total number of ordinary shares in issue and eligible to be voted on at the AGM was 972,930,353.

 

3.   A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against" any resolution nor in the calculation of the proportion of "Total issued share capital voted" for any resolution.

 

4.   The Board appreciates the support shown by shareholders for the resolutions at today's AGM.

 

In accordance with Listing Rule 9.6.2, a copy of the resolutions will shortly be submitted to the National Storage Mechanism and will be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

A copy of the poll results for the AGM will also be available shortly on the Company's website at https://nanoporetech.com/about-us/investors/shareholder-information.

 

 

-ENDS-

For further information please contact:

cosec@nanoporetech.com

ir@nanoporetech.com

 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The Group has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer.  Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture. Oxford Nanopore Technologies products are for Research Use Only (RUO). Products labelled/branded as Oxford Nanopore Diagnostics may be RUO or may be regulated as invitro diagnostic devices in some jurisdictions, please check individual product labelling. For more information, please visit: https://nanoporetech.com/

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings